Statements (51)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:legal_case
|
gptkbp:allows |
specific population studied
short follow-up in some cases |
gptkbp:analysis |
statistical analysis
|
gptkbp:clinical_trial |
highly significant results
NC T01950758 |
gptkbp:collaborations |
various academic institutions
|
gptkbp:collection |
clinical assessments
|
gptkbp:duration |
up to 36 months
|
gptkbp:events |
median 27 months
|
gptkbp:field_of_study |
cardiology
|
gptkbp:focus |
heart failure
|
gptkbp:future_plans |
long-term effects of treatment
comparative effectiveness studies |
https://www.w3.org/2000/01/rdf-schema#label |
PARADIGM-HF
|
gptkbp:impact |
influenced future studies
changed heart failure treatment guidelines |
gptkbp:is_compared_to |
gptkb:enalapril
|
gptkbp:is_protected_by |
gptkb:sacubitril/valsartan
|
gptkbp:is_studied_in |
double-blind
|
gptkbp:is_tested_for |
Phase III
|
gptkbp:launch_date |
2010-12-01
|
gptkbp:location |
multiple countries
|
gptkbp:notable_work |
improved exercise capacity
better symptom control sacubitril/valsartan improved quality of life sacubitril/valsartan reduced cardiovascular death significant reduction in mortality sacubitril/valsartan reduced heart failure hospitalizations |
gptkbp:participants |
hospitalization for heart failure
change in NT-pro BNP levels |
gptkbp:population |
chronic heart failure patients
|
gptkbp:publishes |
gptkb:New_England_Journal_of_Medicine
|
gptkbp:receives_funding_from |
gptkb:Company
|
gptkbp:regulatory_compliance |
FDA approved
EMA approved |
gptkbp:research |
randomized controlled trial
multicenter trial sacubitril/valsartan was superior to enalapril |
gptkbp:result |
gptkb:2014
|
gptkbp:side_effect |
renal impairment
hypotension hyperkalemia |
gptkbp:sponsor |
gptkb:Novartis
|
gptkbp:student_enrollment |
adults with heart failure
approximately 8,442 participants |
gptkbp:treatment |
reduced hospital readmissions
improved overall survival |
gptkbp:year |
2014-12-01
|
gptkbp:bfsParent |
gptkb:Entresto
|
gptkbp:bfsLayer |
4
|